In April, the FDA approved decabtagene vicleucel (ide-cel) for earlier treatment of relapsed/refractory multiple myleoma.
Ariana Pelosci
Advertisement
Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®.
Articles by Ariana Pelosci
The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.
Ivosidenib monotherapy is now approved by the FDA for patients with relapsed/refractory myelodysplastic syndrome with an IDH1 mutation.
Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Upcoming 2026-2027 Vaccine Season: Deals, Data, and an FDA Vote
2
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
3
House Passes Bill to Ease Medicare ACO Digital Quality Reporting Burden
4
Pediatric Cancer Carries Greater Financial Toxicity Than Adult Disease, Driving Calls for Systemic Change
5